Your Cart Is Empty!
The societal and commercial ambitions of orphan drug developers determine which commercial model will best meet their aims. Profit, potential and patient benefit all play a part, so which model is best and what are the considerations which underpin that choice?
This report analyses current orphan drug commercial models, assesses their benefits and challenges, assesses how the market is developing and, with the help of expert input, examines how they benefit “pure play” orphan drug developers and big pharma.
Answering key questions:
Meeting expectations: What factors are vital for orphan drugs commercial teams to ensure that their business model works for all stakeholders?
Key components: What are the key components of current commercial models and how are these evolving?
Hybrid best? What can be learnt from the hybrid (or partnership) commercial strategy as exemplified by Sanofi and Genzyme? Is this the way of the future?
In house: Roche and Novartis are pursuing an integrated strategy - what is the challenge for big pharma in taking this path?
Small developer challenges: What research and market access challenges exist for “pure play” orphan drugs companies and how are they overcoming them?
Assessing success? Profit or patient benefit - what factors are critical for assessing orphan drug success?
Key Topics Explored
Big pharma could learn lessons from smaller orphan drug players in their consultative and inclusive attitude to patients
Size doesn’t matter. The dynamics of the orphan drugs market mean that company size is not a critical factor for success. The market is characterised by a high number of smaller orphan drug companies who are focussing on a range of rare diseases with high unmet needs.
Competition in the rare disease space is now a fact and the market dynamic is changing dramatically. What are the potential negative impacts on the wider orphan drug sector?
The fully integrated commercial model allows access to the resources and reach of big pharma but competing priorities can dilute the attention given to rare diseases.
Tony Hall, Co-founder of FindaCure
Luigi Longinotti, Portfolio Manager – Orphan Drugs at Recordati
Pedro Lendinez Ortega, Products Affairs Manager, Orphan Drugs Especialist en Orphan Europe
Wendy White, SVP Rare Disease Dohmen Life Science Services
Chairman and CEO, Rare Disease Company
Chairman and CEO, Rare Disease Company
VP, Rare Diseases, Biopharmaceutical Company.
CEO and Rare Disease Expert, Bioscience and Biopharmaceutical Company.
Rare Disease Expert, Healthcare regulatory policy and government relations consulting firm
Table of Contents
2 Research objectives and methodology
4 Current structures
4.1 Key findings
4.2 Orphan drugs market overview
4.2.1 What are orphan drugs?
4.2.2 The orphan drugs market is increasing in value
188.8.131.52 There are a large number of orphan drugs being approved each year
184.108.40.206 Some orphan drugs can generate significant revenue
220.127.116.11 New products will continue to drive growth
4.3 Companies involved in orphan drugs
5 Orphan drugs commercial models and leading companies
5.1 Key findings
5.2 There are different structures for orphan drugs companies
5.2.1 A fully integrated model is favoured by larger pharmaceutical companies
5.2.2 Partnership or partially integrated models are being increasingly used.
5.2.3 Independent and focused on orphan drugs
18.104.22.168 Shire: increasing its focus on rare diseases
22.214.171.124 BioMarin: a blueprint for orphan drug success
6 Strategies for success
6.1 Key findings
6.2 Past orphan drugs success has been largely down to the unmet need
6.2.1 Product Acquisition removes the risk but can deliver returns
6.2.2 A focused R&D strategy is essential for success
6.3 Education and awareness is an important part of the commercialisation process
6.3.1 Stakeholder engagement is fundamental for orphan drugs
126.96.36.199 Patients are seen as the most important stakeholder by many
188.8.131.52 Companies have a role to play in educating and supporting physicians
184.108.40.206 Determining the value proposition is an important element for commercial success
6.3.2 A successful model is not necessarily the one that delivers the highest revenues
220.127.116.11 Traditional commercial measures of success are used for orphan drugs
18.104.22.168 Patient outcomes are increasingly important for orphan drugs
7 Key challenges for current orphan drugs models
7.1 Key findings
7.1.1 Pricing of orphan drugs is expected to become more challenging
7.1.2 The orphan drugs market place is becoming more competitive
7.1.3 There are emerging challenges in the approval processes
7.1.4 The definition of an orphan drug is being scrutinised
8 Evolution of commercial models
8.1 Key findings
8.1.1 A more focused model is perceived as being most effective
8.1.2 Patient engagement will continue to be critical for the orphan drugs model
8.1.3 Innovation will be key for future orphan drug success
8.1.4 Out-sourcing commercial activities can maintain focus and competitiveness
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.